Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 610-916-8 | CAS number: 5294-61-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 26 November 2014 - 02 December 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Test method according to OECD Guideline 429. GLP study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- N-(2,6-dimethylphenyl)-2-(piperazin-1-yl)acetamide
- EC Number:
- 610-916-8
- Cas Number:
- 5294-61-1
- Molecular formula:
- C14H21N3O
- IUPAC Name:
- N-(2,6-dimethylphenyl)-2-(piperazin-1-yl)acetamide
- Details on test material:
- - Name of test material (as cited in study report): N-(2,6-dimethylphenyl)-1-(piperazineacetamide)
- Physical state: White solid
- Analytical purity: 99.8 %
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: ELEVAGE JANVIER, Route des Chènes Secs B.P. 4105, 53940 LE GENEST-ST-ISLE (France)
- Age at study initiation: 10 weeks old
- Weight at study initiation: 20.1-21.8 g
- Housing: Group caging / mice were provided with glass tunnel-tubes. Cage type II, polypropylene / polycarbonate.
- Diet (e.g. ad libitum): ssniff® SM Rat/Mouse – “Breeding & Maintenance, 15 mm, autoclavable Complete diet for rats/mice”, ad libitum.
- Water (e.g. ad libitum): tap water, ad libitum.
- Acclimation period: 20 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30 - 70 %
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours of light daily, from 6.00 a.m. to 6.00 p.m.
Study design: in vivo (LLNA)
- Vehicle:
- propylene glycol
- Concentration:
- 10, 25 and 50%.
- No. of animals per dose:
- 4 animals / group.
- Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: The solubility of the test item was examined in a short Preliminary Compatibility Test: AOO (acetone:olive oil 4:1 (v:v)
mixture), N,N-dimethylformamide (DMF), Methyl ethyl ketone (MEK), Propylene glycol (PG), Dimethyl sulfoxide (DMSO) and 1% aqueous Pluronic® PE9200 (1% Pluronic) were tested. The best vehicle was considered to be PG. The highest achievable concentration of the test item was 50 % (w/v).
- Preliminary Irritation/Toxicity Test:
2 animals per dose were exposed to test item concentrations of 50 and 25 % (w/v) in PG. The preliminary experiment was conducted in a similar experimental manner to the main study, but it was terminated on Day 6 with a body weight measurement and the radioactive proliferation assay was not performed. All mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Both ears of each mouse were observed for erythema. Ear thickness was also measured using a thickness gauge on Day 1 (pre-dose), Day 3 (approximately 48 hours after the first dose) and Day 6. Additional quantification of the ear thickness was performed by ear punch weight determination after the euthanasia of the experimental animals. Mortality and signs of systemic toxicity were observed. No marked body weight loss was detected on the mean body weight values of the groups. There were no indications of any irritancy at the site of application. The revealing ear punch weights were within the historical control range. The draining auricular lymph nodes of the animals were visually examined: they were normal for one-one animal in both dose groups and they were slightly enlarged for one-one animal in the groups (subjective judgement by analogy with observations of former experiments). Based on these results, the 50 and 25 % (w/v) doses were considered to be acceptable for the main test. Therefore, 50, 25 and 10 % (w/v) doses were examined in the main test.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Criteria used to consider a positive response: The test item is regarded as a sensitizer if both of the following criteria are fulfilled:
1) That exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than recorded in control mice, as indicated by the stimulation index.
2) The data are compatible with a conventional dose response, although allowance must be made (especially at high topical concentrations) for either local toxicity or immunological suppression.
TREATMENT PREPARATION AND ADMINISTRATION:
During the study, animals were topically dosed with 25 μL of the appropriate formulation using a pipette on the dorsal surface of each ear. Each animal was dosed once a day for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. On Day 6, animals were taken to the radioactive suite and each mouse was intravenously injected via the tail vein with 250 mL of sterile PBS (phosphate buffered saline) containing
approximately 20 mCi of 3HTdR using a gauge 25G x 1" hypodermic needle with 1 mL sterile syringe. Once injected, the mice were left for 5 hours (± 30 minutes). Five hours later, the mice were euthanized and the auricular lymph nodes were extracted from the animals. A single cell suspension (SCS) of pooled lymph node cells (LNCs) was prepared and the samples were examined in a scintillation counter.
OBSERVATIONS
During the study (Day 1 to Day 6) each animal was observed daily for any clinical signs, including local irritation and systemic toxicity. Clinical observations were performed twice a day (before and after treatments) on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Individual body weights were recorded on Day 1 (beginning of the test) and on Day 6 (prior to 3HTdR injection).
EVALUATION OF RESULTS
Radioactive disintegrations per minute (DPM) was measured for each pooled group of nodes. The results were expressed as “DPN” (DPM divided by the number of lymph nodes) following the industry standard for data presentation. Stimulation index (SI = DPN value of a treated group divided by the DPN value of the negative control group) for each treatment group was also calculated. A stimulation index of 3 or greater is an indication of a positive result. Since the test item gave a positive response and data permitted, the EC3 value of the test item was calculated (EC3 means the effective chemical concentration required for SI=3). - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
Results and discussion
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Remarks on result:
- other: The stimulation index values were 4.2, 2.3 and 1.7 at concentrations of 50, 25 and 10 % (w/v), respectively.
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Test item 50 % (w/v) in PG: 8636.5 DPM Test item 25 % (w/v) in PG: 4661.5 DPM Test item 10 % (w/v) in PG: 3463.5 DPM
Any other information on results incl. tables
Clinical observations:
No mortality or signs of systemic toxicity were observed during the study. Minimal amount of test item precipitate was observed on the ears of the animals in the 50 % (w/v) dose group on Days 3-5.
Body weight measurement:
No treatment related effects were observed on the body weight changes of the experimental animals.
Proliferation assay:
Test Group Name |
Measured DPM / group |
DPM |
Number of lymph nodes |
DPN |
Stimulation Index |
Background (5 % (w/v) TCA) |
30 31 |
- |
- |
- |
- |
Negative (vehicle) control (PG) |
2091 |
2060.5 |
8 |
257.6 |
1.0 |
Test item 50 % (w/v) in PG |
8667 |
8636.5 |
8 |
1079.6 |
4.2 |
Test item 25 % (w/v) in PG |
4692 |
4661.5 |
8 |
582.7 |
2.3 |
Test item 10 % (w/v) in PG |
3494 |
3463.5 |
8 |
432.9 |
1.7 |
Positive control (25 % (w/v) HCA in PG) |
12700 |
12669.5 |
8 |
1583.7 |
6.1 |
The stimulation index values were 4.2, 2.3 and 1.7 at concentrations of 50, 25 and 10 % (w/v), respectively.
The obtained data are compatible with a conventional dose response and allow the calculation of the EC3 value according to an adequate scientific method. EC3 means the effective chemical concentration required for SI=3. The calculated EC3 value of the test substance is 34.2 % (w/v).
The appearance of the lymph nodes was normal in the negative (vehicle) control group and in the 10 % (w/v) group. Slightly enlarged lymph nodes were detected in the 50 and 25 % (w/v) groups. Larger than normal lymph nodes were observed in the positive control group.
The DPN values observed for the vehicle and positive control substance in this experiment were within the historical control range. No mortality, cutaneous reactions or signs of toxicity were observed for the positive control substance in the study. A significant lymphoproliferative response (stimulation index value of 6.1) was noted for HCA in the main experiment. This value was considered to confirm the appropriate performance of the assay.
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The test item was shown to have sensitisation potential (sensitizer) in the Local Lymph Node Assay. The stimulation index values were 4.2, 2.3 and 1.7 at concentrations of 50, 25 and 10 % (w/v), respectively. The calculated EC3 value was 34.2 % (w/v).
- Executive summary:
The skin sensitisation test following dermal exposure was performed according to OECD Guideline 429 and EU method B.42, following the Principles of GLP. Based on the results of the Preliminary Compatibility Test, the test item was formulated in Propylene glycol (PG) at a highest achievable concentration of 50% (w/v). The Preliminary Irritation / Toxicity Test was performed in CBA/J Rj mice using two doses: 50 and 25 % (w/v) in PG. Based on the observations recorded in the preliminary test, the 50 % (w/v) was selected as top dose for the main test. In the main assay, twenty female CBA/J Rj mice were allocated to five groups of four animals each: three groups received the test substance formulated in PG at 50, 25 and 10 % (w/v) concentrations; the negative control group received the vehicle (PG); the positive control group received 25 % (w/v) HCA (dissolved in PG). The test item solutions were applied on the dorsal surface of ears of experimental animals (25 μL/ear) for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. The cell proliferation in the local lymph nodes was measured by incorporation of tritiated methyl thymidine (3HTdR) and the values obtained were used to calculate stimulation indices (SI). No mortality or signs of systemic toxicity were observed during the study. Minimal amount of test item precipitate was observed on the ears of the animals in the 50 % (w/v) dose group on Days 3-5. No treatment related effects were observed on the body weight changes of the experimental animals. The stimulation index values were 4.2, 2.3 and 1.7 at concentrations of 50, 25 and 10 % (w/v), respectively. The calculated EC3 value was 34.2 % (w/v). All validity criteria were fulfilled. In conclusion, under the conditions of the present assay the test item, tested in a suitable vehicle, was shown to have sensitisation potential (sensitizer) in the Local Lymph Node Assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
